{"id":"W4409822072","doi":"10.1158/1538-7445.am2025-ct188","title":"Abstract CT188: BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Antibody-drug conjugate; Behold; Conjugate; Drug; Radioimmunotherapy; Solid tumor; Oncology; Internal medicine; Cancer; Antibody; Monoclonal antibody; Pharmacology; Immunology; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088391,0.001485332,0.001272394,0.000453678,0.0003049649,0.0006992462,0.0007599479,0.0009198004,0.005556663],"category_scores_gemma":[0.0007161177,0.0004658619,0.0008425488,0.0003555437,0.0006960077,0.0006449973,0.0002539505,0.00286228,0.0009442393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001136659,"about_ca_system_score_gemma":0.00143106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001519224,"about_ca_topic_score_gemma":0.004458495,"domain_scores_codex":[0.9997533,0.00009600989,0.00001129446,0.00005142255,0.0000313979,0.00005661198],"domain_scores_gemma":[0.9996146,0.00005535156,0.00006213309,0.00002487791,0.00002575373,0.0002172892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5818601,0.09026124,0.009541152,0.001681417,0.001681724,0.0006471342,0.0006155259,0.0058452,0.13088,0.0008605762,0.01332772,0.1627981],"study_design_scores_gemma":[0.5298275,0.4390669,0.01255221,0.00005351064,0.0004542154,0.0004778999,0.00007408938,0.001736512,0.01013227,0.0003047885,0.005278793,0.00004138556],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913557,0.001933622,0.0005884652,0.0004412231,0.0001004425,0.001797235,0.001469541,0.0001299187,0.002183948],"genre_scores_gemma":[0.9875102,0.001637505,0.001719908,0.0006613823,0.00009491458,0.001571879,0.002584561,0.00003367812,0.004186025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005556663,"threshold_uncertainty_score":0.0185889,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02251589590315796,"score_gpt":0.3659990951510461,"score_spread":0.3434831992478882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}